Van ECK Associates Corp reduced its stake in Qiagen (NYSE:QGEN – Free Report) by 15.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 185,221 shares of the company’s stock after selling 33,210 shares during the period. Van ECK Associates Corp owned approximately 0.08% of Qiagen worth $7,801,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after buying an additional 500 shares in the last quarter. Toronto Dominion Bank purchased a new stake in shares of Qiagen during the second quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the period. CWM LLC lifted its position in shares of Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares in the last quarter. Finally, Headlands Technologies LLC boosted its stake in shares of Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.
Qiagen Price Performance
Shares of NYSE QGEN opened at $43.87 on Thursday. The business has a 50 day simple moving average of $44.11 and a 200-day simple moving average of $43.70. Qiagen has a twelve month low of $37.51 and a twelve month high of $47.44. The company has a market capitalization of $10.01 billion, a price-to-earnings ratio of 145.98, a price-to-earnings-growth ratio of 3.33 and a beta of 0.41. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27.
Analysts Set New Price Targets
View Our Latest Stock Report on QGEN
About Qiagen
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Stories
- Five stocks we like better than Qiagen
- What Is WallStreetBets and What Stocks Are They Targeting?
- What a Trump Win Looks Like for the Market Now and Into 2025
- How to buy stock: A step-by-step guide for beginners
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- Insider Trading – What You Need to Know
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGEN – Free Report).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.